INNOVATE walked into this earnings season priced like a problem stock. The shares had barely moved over the past quarter and traded at a very low 0.1x price to sales. Then Q2 landed and the stock rose 63% in a single session after the release, as the company swung to a quarterly profit.

The key takeaway is straightforward: INNOVATE generated Q2 revenue of US$421.6m and reported basic earnings per share of US$0.78, a sharp turn from recent losses. That profit result, alongside strong adjusted EBITDA, is what just rewired the market’s view.

Impressed by INNOVATE's sharp swing back to profit but unsure how it stacks up against other potential turnarounds with steadier fundamentals? Take a look at our curated list of list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$421.6m vs. US$242.0m (very large increase)
• Net Income, Q2 2026 vs. Q2 2025: Profit of US$10.4m vs. loss of US$22.0m (returned to profit)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.78 vs. loss of US$1.67 per share (returned to profit per share)
• Adjusted EBITDA, Q2 2026 vs. Q2 2025: US$46.3m vs. US$15.7m (very large increase in earnings before interest, tax, depreciation and amortisation, also called EBITDA)

Prefer clear visuals instead of another wall of earnings tables and footnotes? Get a full picture of how INNOVATE's valuation compares using an easy, chart-based view through our company report for INNOVATE.

INNOVATE earnings reset supports cautious optimism

The latest quarter gives supporters of INNOVATE something concrete to point to. Revenue of US$421.6m and a return to profit align with the idea that infrastructure and hard assets can carry the group while life sciences develops. Infrastructure is doing the heavy lifting with higher EBITDA and a larger backlog, which fits the view of this as the anchor segment. The strong single day share price reaction suggests investors were waiting for proof that execution across the portfolio can translate into cleaner, profitable results.

Risks remain around leverage and life sciences drag

The bearish angle is not fully defused. Life sciences revenue declined year on year and still needs funding support, which keeps execution and dilution risk on the table. Total debt of US$626.4m and modest cash outside operating units limit room for error until the broadcasting sale closes. Broadcasting contributes little EBITDA yet carries financing complexity, so delays or changes to the CONX deal would matter. For now, the numbers point to a healthier core at INNOVATE, but with meaningful balance sheet and capital allocation questions still in play.

Review whether INNOVATE's leverage, negative equity, and volatile share price are isolated issues or part of deeper structural pressures. Scan the risk analysis for INNOVATE which shows 2 important warning signs.

Take Control Of Your Next Move

If INNOVATE's sharp swing back to profit has your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value and watch for a better entry point. After you decide to buy or sell, keep your focus with the Portfolio Command Center that cuts through market noise and flags the updates that matter most to your holdings. For a longer term view, tap into shared insights and different angles on INNOVATE through the Community so you are not thinking in isolation. By spotting potential catalysts and risks early, you give yourself a better chance to stay ahead of the market.

Seeking Fresh Alternatives Beyond INNOVATE?

Some stocks are already building breakout momentum while others are still flying under the radar for now. Spot the ones that matter before the crowd moves and act now.

• Capture potential cash rich compounders by scanning a curated 49 high quality undervalued stocks that combines sturdy balance sheets with earnings power before the stories get fully priced in.
• Target resilient compounding candidates through a pre filtered 78 resilient stocks with low risk scores that focuses on businesses with steadier profiles while prices still reflect hesitation.
• Consider the picks and shovels side of AI by reviewing a focused shortlist of 55 AI infrastructure stocks before capital flows adjust pricing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.